Hope fades for 18 on Indian submarine after blasts, fire
MUMBAI (Reuters) - India's navy chief held out little hope for survivors on a submarine after some of its weapons detonated accidentally and fire swept through it. The likely deaths...
Home > Reviews
All Stories
India revokes patents on Allergan eye drugs Ganfort and Combigan
MUMBAI (Reuters) - India revoked patents on two of Allergan Inc's eye drugs on Thursday, the latest in a series of intellectual property setbacks suffered by Western drugmakers. India's patent...
India revokes patents on Allergan eye drugs Ganfort and Combigan
MUMBAI (Reuters) - India revoked patents on two of Allergan Inc's eye drugs on Thursday, the latest in a series of intellectual property setbacks suffered by Western drugmakers. India's patent...
India’s Sun Pharma in talks to buy Sweden’s Meda for $5-$6 billion: sources
MUMBAI (Reuters) - India's Sun Pharmaceutical Industries Ltd is in talks to buy Sweden's Meda AB for between $5 billion and $6 billion to boost its generics business in developed...
Exclusive: Indian firm in global ATM heist admits system breached
PUNE, India (Reuters) - An Indian payment card processing company acknowledged on Monday that hackers breached its security to increase the limits on some pre-paid card accounts in a global...
India’s top court dismisses Novartis plea for Glivec patent
NEW DELHI/MUMBAI (Reuters) - India's top court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms...
India’s top court dismisses Novartis plea for Glivec patent
NEW DELHI/MUMBAI (Reuters) - India's top court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms...
BDR Pharma seeks India license for Bristol-Myers drug
MUMBAI (Reuters) - BDR Pharmaceuticals said on Monday it has applied to India's patent office for a compulsory license to sell a generic version of Bristol-Myers Squibb Co's cancer drug...
BDR Pharma seeks India license for Bristol-Myers drug
MUMBAI (Reuters) - BDR Pharmaceuticals said on Monday it has applied to India's patent office for a compulsory license to sell a generic version of Bristol-Myers Squibb Co's cancer drug...
Slow approvals put India’s drug trials industry at risk
MUMBAI/NEW DELHI (Reuters) - Slower government approval for testing new medicines is threatening India's aspirations to be a fast-growing, low-cost hub for clinical trials, and has prompted some drugs firms...